Key facts
- It has raised $7.9M; the latest was Seed Round ($7.9M) in Nov 2025.
- Notable investors include Zürcher Kantonalbank, Ventura BioMed Investors, ZEISS Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Arcoris bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Arcoris bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arcoris bio
Developer of nanotechnology reagents and protocols designed for the enhanced and simultaneous detection of RNA and protein within biological samples. The company's platform incorporates a nanotechnology-based signal amplification system that permits real simultaneous multiplex detection of targets, is multimodal for applications such as immunofluorescence and imaging mass cytometry, and is designed for ease of use while requiring no specialized laboratory equipment, enabling scientific researchers in cell biology and genomics to perform accurate, high-throughput biomolecule quantification that complements other data analysis methods like RNA sequencing.
- Sector
- Healthcare
- HQ
- Schlieren, Switzerland
- Founded
- 2022
- Employees
- 10
- Website
- arcorisbio.com/
- Ownership
- Privately Held (backing)
Arcoris bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arcoris bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arcoris bio in its N-PORT filings yet. We sweep new filings monthly.